Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Long-Term Investments (2022 - 2024)

OptimizeRx's Long-Term Investments history spans 3 years, with the latest figure at $434000.0 for Q2 2024.

  • For Q2 2024, Long-Term Investments changed N/A year-over-year to $434000.0; the TTM value through Jun 2024 reached $434000.0, changed N/A, while the annual FY2023 figure was $568000.0, 98.98% down from the prior year.
  • Long-Term Investments for Q2 2024 was $434000.0 at OptimizeRx, down from $501000.0 in the prior quarter.
  • Across five years, Long-Term Investments topped out at $55.9 million in Q4 2022 and bottomed at $434000.0 in Q2 2024.
  • The 3-year median for Long-Term Investments is $568000.0 (2023), against an average of $11.6 million.
  • The largest YoY upside for Long-Term Investments was 98.98% in 2023 against a maximum downside of 98.98% in 2023.
  • A 3-year view of Long-Term Investments shows it stood at $55.9 million in 2022, then tumbled by 98.98% to $568000.0 in 2023, then decreased by 23.59% to $434000.0 in 2024.
  • Per Business Quant, the three most recent readings for OPRX's Long-Term Investments are $434000.0 (Q2 2024), $501000.0 (Q1 2024), and $568000.0 (Q4 2023).